Current role of antifibrotic drugs in lung cancer and fibrosing interstitial lung diseases (fILD)
| Statement | Current status |
| Improves outcomes by improving fILD outcomes | Definite effect |
| May improve outcomes by protecting against acute exacerbation with lung cancer treatments: | |
| Cancer resection | Proof of concept |
| Chemotherapy | Attractive hypothesis |
| Radiotherapy | Hypothesis |
| May have worthwhile standalone antitumour effects: | |
| In vitro and animal data | Attractive hypothesis |
| Reduced occurrence of cancer in pirfenidone-treated patients | Proof of concept? |
| Antitumour effects in NSCLC with nintedanib | Proof of concept? |
| May also increase the incidence of lung cancer/fILD due to prolonged survival | Attractive hypothesis |
NSCLC: nonsmall cell lung cancer.